Posted on 14/07/2009 in Pharmaceutical Company Product News Recordati Pharmaceuticals has signed a deal with international pharmaceutical group Amdipharm for the sales and marketing rights to TransAct local action transcutaneous (LAT) in a number of regions.
In a statement, the organisation explained that TransAct LAT is a transdermal patch that contains 40 mg of flurbiprofen, which is a widely prescribed non-steroidal anti-inflammatory drug.
TransAct LAT is used for the relief of pain relating to the musculoskeletal system.
The company said: "Recordati has an established franchise in pain and inflammation management and the addition of this product provides a valid further choice for the medical practitioner."
Founded in 2002, Amidpharm has a portfolio of more than 60 products, which it states generate sales in more than 100 countries around the world.
Earlier this month, Recordati Pharmaceuticals announced that its Arrigo Recordati international prize for scientific research has been awarded to Valentin Fuster, director of the Mount Sinai Heart facility in New York.Other news stories from 14/07/2009
Read more in the Zenopa News Archive
How this news is generated
|
